CORPORATE OVERVIEW

JPM Healthcare Conference 2024

COPYRIGHT © ABCELLERA

DISCLAIMER

This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

COPYRIGHT © ABCELLERA

The **most important drivers** of productivity in drug development are:

New insights into the biology of disease

Novel solutions to challenging problems

COPYRIGHT © ABCELLERA

We have built an engine to generate **first-in-class** and **best-in-class antibody medicines**.



Build a competitive advantage

Investments in technological capability can **improve the productivity of drug development**.

So you can solve hard problems

Long-term value creation comes from being able to repeatedly **deliver first-in-class and best-in-class products**.

COPYRIGHT © ABCELLERA

AbCellera's engine is broadly applicable within the $400B[1] antibody therapeutics market.

- 11+ years of investment in **technology, teams, and infrastructure**
- Vertical integration from concept to clinic
- Validated on **100+ therapeutic programs**
- Leading capabilities on **difficult targets and bispecifics**

Capitalization

$1B+* in liquidity

$200M+ from non-dilutive government funding

$800M+ in total cash, equivalents, and marketable securities

Portfolio of Partnered Programs

110* partner-initiated discovery program starts**

10* molecules in the clinic

Technology & Infrastructure

$500M+ platform investments

~600 employees across 3 countries

1 engine for end-to-end discovery, development & clinical manufacturing

Portfolio of Internal Programs

12† internal program starts

2 assets in IND-enabling studies

[1]Market Size by 2030 *Source: IQVIA* * As of September 30, 2023; † As of December 31, 2022 ** With downstream participation

COPYRIGHT © ABCELLERA

We are increasingly focused on strategic partnerships.

We look for partnerships that bring new insights into novel biology or access to unique capabilities to create opportunities in therapeutic areas of shared interest.

Lilly AbbVie REGENERON
NOVARTIS Incyte Abdera Therapeutics
EMPIRICO Prelude THERAPEUTICS

Expanding relationships
with large pharma and large biotech

T-cell engager platform
deals in oncology and autoimmune conditions

Co-development
to access new targets and technology

Company creation
with top-tier venture capital groups

COPYRIGHT © ABCELLERA

Advancing an internal pipeline of potential **first-in-class** and **best-in-class** assets is a top priority to drive **growth**.

First two IND submissions anticipated in 2025.

We intend to take additional **first-in-class** development candidates into IND-enabling studies in 2024 and 2025.

$220M in non-dilutive funding from governments of Canada and British Columbia.

MOLECULE	TARGET	INDICATION	THERAPEUTIC AREA	POTENTIAL DIFFERENTIATION
ABCL575	**OX40L**	atopic dermatitis	immunology & inflammation	best in class
IND-ENABLING				
ABCL635	undisclosed **GPCR or ion channel**	undisclosed	metabolic & endocrine conditions	first in class
IND-ENABLING				

COPYRIGHT © ABCELLERA

ABCL575 is a potential **best-in-class** and second-in-class antibody therapy for the treatment of atopic dermatitis.

Molecule	ABCL575
Status	IND-enabling studies (Preclinical)
Target	OX40 ligand (OX40L)
MOA	Blocking and non-depleting
Indication	• Atopic dermatitis (AD) • Other indications in autoimmunity and inflammation
Therapeutic Area	Immunology & inflammation
Market Opportunity	$17B by 2032*
Potential Differentiation	ABCL575 has been designed with potency, pharmacokinetics, and developability to **enable less frequent dosing**, which provides a potential for differentiation.
Summary	Targeting OX40L has the potential to address a broad range of inflammatory conditions and autoimmune diseases, some of which include **colitis/inflammatory bowel disease (IBD), asthma/atopy, and diabetes**[1]. OX40L blocking is currently under investigation for **atopic dermatitis**[2], **asthma**[2], **alopecia areata**[3], **hidradenitis suppurativa (HS)**[4].

*Source: IQVIA

1. Croft M, et al. (2009) Immunol Rev. 229(1):173-91.
2. https://clinicaltrials.gov/search?intr=Amlitelimab
3. https://clinicaltrials.gov/search?intr=IMG-007
4. https://clinicaltrials.gov/search?intr=%20SAR-442970

COPYRIGHT © ABCELLERA

A potential **first-in-class** antibody therapy for metabolic and endocrine conditions.

ABCL635 is the first AbCellera-led asset derived from our GPCR and ion channel platform.

Molecule	ABCL635
Status	IND-enabling studies (Preclinical)
Target	Undisclosed - GPCR or ion channel
MOA	Antagonist
Indication	Undisclosed
Therapeutic Area	Metabolic & endocrine conditions
Market Opportunity	>$2B
Potential Differentiation	First-in-class
Summary	Program details and indication will only be disclosed once the molecule reaches the clinic.

COPYRIGHT © ABCELLERA

Continued progress and differentiation for T-cell engager platform.

T-cell engagers have tremendous potential for the treatment of cancer and autoimmune conditions but are technically challenging to design and engineer.

AbCellera's T-cell engager platform combines unique discovery capabilities, bispecific engineering, and a panel of hundreds of diverse CD3-binding antibodies to potentially:

Improve the safety profile of T-cell engagers

by creating bispecific antibodies that achieve **potent tumor killing with reduced cytokine release**, which can help address dose-limiting toxicity.

Expand the accessible target space for T-cell engagers in solid tumors

by enabling discovery of antibodies that are **highly specific to MHC-peptide complexes.**

COPYRIGHT © ABCELLERA

Reducing dose-limiting toxicity associated with cytokine release.

Selection of CD3 binders that achieve potent cell killing with very low cytokine release on an undisclosed target.

Example molecule

Potent tumor-cell killing



Low cytokine release





COPYRIGHT © ABCELLERA

Expanding the target space:

Discovery platform enables generation of diverse and highly specific pMHC binders.

Example molecules





MAGE-A4⁺ cells

- AbCellera molecules
- Molecule R

MAGE-A4 knockout cells

- AbCellera molecules
- Molecule R

COPYRIGHT © ABCELLERA

Continued focus on **high-value programs and strategic partnerships.**

With our **differentiated technology** position and **$1B+ in liquidity**, we have a long cash runway for focused **strategic investment and execution.**

Completion of Engine

Over the next 2 years we will continue to invest in the **final stage of our engine**, including construction and commissioning of our manufacturing facility.

Our Portfolio of Partnered Programs

In 2024, we anticipate partnership deals from our T-cell engager platform.

Our partnership strategy is to focus on **select high value strategic partnerships**, not deal volume.

Our Portfolio of Internal Programs

We expect ABCL575 and ABCL635 to enter clinical development in 2025.

In 2024n and 2025, we expect **additional first-in-class** development candidates from our **GPCR and ion channel platform**.

COPYRIGHT © ABCELLERA

THANK YOU



COPYRIGHT © ABCELLERA